What is Terran Biosciences?
Terran Biosciences operates as a sophisticated biotech platform dedicated to the advancement of transformative therapeutics for patients suffering from complex neurological and psychiatric conditions. The company maintains a diverse and robust portfolio, which includes late-stage therapies for schizophrenia and selective serotonin 2A receptor antagonists. Beyond its drug development efforts, the firm has integrated a proprietary drug design engine that facilitates the creation of first-in-class and best-in-class psychedelic therapies. Furthermore, the company leverages an AI-enabled imaging software platform to enhance diagnostic precision and clinical trial outcomes. Led by a team of seasoned biopharma professionals and physician-entrepreneurs, Terran Biosciences is strategically positioned to lead the current renaissance in neuroscience research and development.
How much funding has Terran Biosciences raised?
Terran Biosciences has raised a total of $9M across 1 funding round:
Angel/Seed
$9M
Angel/Seed (2025): $9M with participation from Magnetic Ventures and Bruker
Key Investors in Terran Biosciences
Magnetic Ventures
Magnetic Ventures is a female-founded venture capital firm that partners with early-stage founders to leverage AI, machine learning, and next-gen biotech for healthcare innovation.
Bruker
Bruker Corporation is a global leader in scientific instrumentation, analytical technologies, and diagnostic solutions, serving customers across research, industry, and government.
What's next for Terran Biosciences?
With this latest infusion of capital, Terran Biosciences is poised to transition into a more aggressive phase of clinical execution and commercial scaling. The company's roadmap likely involves advancing its late-stage schizophrenia assets through regulatory milestones while simultaneously scaling its AI-driven imaging capabilities. By leveraging the expertise of its strategic partners, the firm is expected to deepen its footprint in the psychedelic medicine space, a sector currently experiencing rapid regulatory and market maturation. Future growth will likely be defined by the successful transition of its pipeline candidates into late-stage clinical trials and the potential for strategic licensing agreements that validate its drug design engine. As the company matures, its ability to integrate advanced computational tools with traditional clinical pharmacology will remain a key differentiator in the competitive biotech landscape.
See full Terran Biosciences company page
